Literature DB >> 9773807

Comparison between short or long exposure to 5-fluorouracil in human gastric and colon cancer cell lines: biochemical mechanism of resistance.

A Harstrick1, A Gonzales, N Schleucher, U Vanhoefer, K Lu, J L Formento, G Milano, H Wilke, S Seeber, Y Rustum.   

Abstract

Recent preclinical and clinical data indicate that the main mechanisms of 5-fluorouracil (5-FU) cytotoxicity depend on the mode of administration. To gather further insight into the major causes of acquired 5-FU resistance, drug-sensitive human gastric (M2), colon (HT29) and breast (MCF7) cancer cell lines were repeatedly exposed to a fixed concentration of 5-FU given either for 1 or 24 h. Although equieffective doses (IC50) of 5-FU were used, resistance to a 1 h exposure of 5-FU developed faster in all models than to a 24 h exposure. Cell lines with acquired resistance to a 1 h application of 5-FU were only partly cross-resistant to a 24 h exposure, whereas lines with resistance to protracted application of 5-FU displayed significant cross-resistance to the 1 h schedule. Resistance to methotrexate was only seen in cell lines with acquired resistance to 24 h of 5-FU. All 5-FU-resistant cell lines showed reduced incorporation of 5-FU into cellular RNA. Furthermore, elevations of thymidylate synthase were seen in all cell lines with resistance to 24 h of 5-FU but also in one cell line with resistance to a bolus schedule. No alterations in folylpolyglutamate synthase developed in the resistant cell lines. These data support the concept that the main mechanisms of 5-FU cytotoxicity depend on the mode of application. Incorporation of fluorouridine triphosphate into RNA appears to be the most important mechanism of action for 5-FU bolus schedules, whereas inhibition of thymidylate synthase becomes more important as the infusion time is prolonged. These data could have implications on the interaction of 5-FU given at different schedules with various other cytostatic agents.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9773807     DOI: 10.1097/00001813-199808000-00008

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  6 in total

1.  Methionine-dependence and combination chemotherapy on human gastric cancer cells in vitro.

Authors:  Wei-Xin Cao; Jing-Min Ou; Xu-Feng Fei; Zheng-Gang Zhu; Hao-Ran Yin; Min Yan; Yan-Zhen Lin
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

2.  Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients.

Authors:  Joana Savva-Bordalo; João Ramalho-Carvalho; Manuela Pinheiro; Vera L Costa; Angelo Rodrigues; Paula C Dias; Isabel Veiga; Manuela Machado; Manuel R Teixeira; Rui Henrique; Carmen Jerónimo
Journal:  BMC Cancer       Date:  2010-09-01       Impact factor: 4.430

Review 3.  Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer.

Authors:  Feng Wen; Qiu Li
Journal:  World J Gastroenterol       Date:  2016-06-21       Impact factor: 5.742

4.  The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity.

Authors:  S Hamzic; N Wenger; T K Froehlich; M Joerger; S Aebi; C R Largiadèr; U Amstutz
Journal:  Pharmacogenomics J       Date:  2016-03-22       Impact factor: 3.550

5.  Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study.

Authors:  Tormod Kyrre Guren; Maria Thomsen; Elin H Kure; Halfdan Sorbye; Bengt Glimelius; Per Pfeiffer; Pia Österlund; Fridbjörn Sigurdsson; Inger Marie Bowitz Lothe; Astrid Marie Dalsgaard; Eva Skovlund; Thoralf Christoffersen; Kjell Magne Tveit
Journal:  Br J Cancer       Date:  2017-04-11       Impact factor: 7.640

6.  Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study.

Authors:  Maria Grazia Cerrito; Marco De Giorgi; Davide Pelizzoni; Sara Maria Bonomo; Nunzio Digiacomo; Arianna Scagliotti; Cristina Bugarin; Giuseppe Gaipa; Emanuela Grassilli; Marialuisa Lavitrano; Roberto Giovannoni; Paolo Bidoli; Marina Elena Cazzaniga
Journal:  Oncotarget       Date:  2018-06-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.